September 24, 2012
According to the RepTrack Survey by Anterio Inc., which conducts research on the recollections of doctors on drug detailing activities, Novartis Pharma’s DPP-4 (dipeptidyl peptidase-4) inhibitor Equa (vildagliptin) ranked first in both the GP market (medical institutions with 99 beds...read more